发明公开
- 专利标题: IRX-2 MODIFIED MANUFACTURING PROCESS
- 专利标题(中): IRX-2改性制造工艺
-
申请号: EP09743225.6申请日: 2009-04-14
-
公开(公告)号: EP2276850A2公开(公告)日: 2011-01-26
- 发明人: FENNINGTON, George, J. , BRANDWEIN, Harvey, J.
- 申请人: IRX Therapeutics, Inc.
- 申请人地址: 140 West 57th Street Suite 9C New York, NY 10019 US
- 专利权人: IRX Therapeutics, Inc.
- 当前专利权人: IRX Therapeutics, Inc.
- 当前专利权人地址: 140 West 57th Street Suite 9C New York, NY 10019 US
- 代理机构: Austin, Hedley William
- 优先权: US44674 20080414
- 国际公布: WO2009137238 20091112
- 主分类号: C12P21/04
- IPC分类号: C12P21/04 ; C12N5/02 ; C12N13/00
摘要:
A highly efficient method of making a primary cell derived biologic by purifying mononuclear cells (MNCs) in a automated cell processor to remove contaminating cells by loading leukocytes onto lymphocyte separation medium (LSM) and centrifuging the medium to obtain purified MNCs, storing the MNCs overnight in a closed sterile bag system, stimulating an induction mixture of the MNCs with phytohemagglutinin (PHA) or other mitogen and ciprofloxacin in a scalable cell culture device and producing a primary cell derived biologic from the MNCs, removing the mitogen from the induction mixture by filtering, incubating the induction mixture, clarifying the induction mixture by filtering to obtain a primary cell derived biologic supernatant, and clearing the primary cell derived biologic supernatant from adventitious agents by anion exchange chromatography, filtration. A closed system prevents contamination of the resulting primary cell derived biologic. An automated method of purifying cells. A method of scalably inducing cells.
公开/授权文献
- EP2276850B9 IRX-2 MODIFIED MANUFACTURING PROCESS 公开/授权日:2013-10-30
信息查询